Clinical Trial Goal
To find out if reduced-intensity allogeneic BMT with post-transplant cyclophosphamide is safe and works well to treat blood cancers.
You may be able to join this trial if you:
- Are 75 years old or younger
- Have a blood cancer. Some examples include:
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CML)
- Chronic myeloid leukemia (CLL)
- Multiple myeloma
- Myelodysplastic syndrome (MDS)
- Myelofibrosis
- Myeloproliferative neoplasm (MPN)
- Non-Hodgkin lymphoma (NHL) including:
- Burkitt lymphoma
- Follicular lymphoma
- Marginal zone lymphoma (MZL)
- T-cell lymphoma (TCL)
- Plasma cell leukemia
- Have not had an allogeneic BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cyclophosphamide is a chemotherapy (chemo) drug that helps prevent GVHD and blocks the growth of cancer cells.
Fludarabine is a chemo drug that blocks the growth of cancer cells.
Mycophenolate mofetil and sirolimus are drugs that slow down the immune system.
Fludarabine is a chemo drug that blocks the growth of cancer cells.
Mycophenolate mofetil and sirolimus are drugs that slow down the immune system.
Before transplant, you’ll get standard treatment with the following:
- Cyclophosphamide – Given as an intravenous (IV) infusion 1 time
- Fludarabine – Given as IV infusions 1 time each day for 5 days
- Total body irradiation (TBI) – A treatment done 1 time, the day before transplant to prepare your body for transplant
On transplant day, the blood-forming cells from your donor are given to you through an IV infusion.
After transplant, you’ll get:
- Cyclophosphamide – Given as an IV infusion 1 time each day for 2 days
- Mycophenolate mofetil - Give as an IV infusion or pill you take by mouth for about 1 month
- Sirolimus - A pill that you take by mouth for 2 months
You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial.
Locations
Masonic Cancer Center at University of MinnesotaRECRUITING
Minneapolis, Minnesota
Mark Juckett
Sponsors
lead: Masonic Cancer Center, University of Minnesota

